In 2016, Personalized Medicine Saw More CDx Deals, Flexible FDA, No LDT Guidance | GenomeWeb

NEW YORK (GenomeWeb) – The importance of diagnostics in supporting precision medicine became more apparent in 2016, as pharmaceutical companies increasingly incorporated biomarker strategies into their therapeutic development programs and as the US Food and Drug Administration demonstrated flexibility and speed in its approvals of codeveloped products (see chart below).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.